Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?

·4-min read

A U.S. Food and Drug Administration (FDA) advisory committee has reviewed Johnson & Johnson's (NYSE: JNJ) data supporting boosters of its COVID-19 vaccine. The FDA gets the final say in the matter, though. In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss J&J's prospects for authorization of boosters.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting